Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 11/26/2025

Radiation Therapy Indications After Breast Surgery

Introduction to Radiation Therapy

  • The American College of Oncology recommends radiation therapy after breast-conserving surgery for invasive breast cancer, while post-mastectomy radiation is indicated for patients with ≥4 positive nodes, T3-T4 tumors, or 1-3 positive nodes with additional risk factors 1, 2

After Breast-Conserving Surgery (BCS)

  • Whole breast radiation therapy (WBRT) is strongly recommended after BCS for invasive cancer, reducing local recurrence risk by two-thirds and improving survival 1, 3, 4, 5
  • Standard dose: 45-50 Gy in 25-28 fractions OR hypofractionated 15-16 fractions with 2.5-2.67 Gy per fraction 2, 4, 5
  • Boost irradiation provides an additional 50% reduction in local recurrence risk and is strongly indicated for patients with unfavorable risk factors, such as grade 3 tumors, vascular/lymphovascular invasion, or close or focally positive margins 1, 4, 5
  • Typical boost dose: 10-16 Gy in 2 Gy fractions 1, 4, 6

After Mastectomy

  • Post-mastectomy radiation therapy (PMRT) is clearly indicated for patients with ≥4 positive axillary lymph nodes or T3-T4 tumors (>5 cm or chest wall/skin involvement), independent of nodal status 1, 2, 3, 6, 7
  • PMRT should be considered for patients with 1-3 positive axillary nodes, particularly when additional risk factors are present, such as young age, vascular/lymphovascular invasion, or low number of examined axillary lymph nodes 1, 2, 3, 6, 7

Regional Nodal Irradiation

  • Supraclavicular nodes should be included in radiation therapy when there is extensive axillary involvement (N≥2) or multiple positive nodes 1, 2, 6
  • Internal mammary nodes should be included when there is documented metastatic spread to this region or medial or central tumor location with axillary node involvement 1, 2, 6, 8

Important Considerations

  • Hypofractionation (shorter fractionation schemes) is validated and generally recommended, though data are limited in young patients and those receiving regional nodal irradiation 2, 4, 5
  • Partial breast irradiation (PBI/APBI) should only be used in carefully selected patients ≥50 years with unicentric, unifocal, node-negative, non-lobular cancer ≤3 cm without extensive intraductal component or lymphovascular invasion 2, 7

Radiotherapy Omission in Breast-Conserving Surgery

  • The American College of Oncology recommends postoperative radiotherapy after breast-conserving surgery for the vast majority of patients with invasive breast cancer, with Level I, Grade A evidence and 100% consensus among guideline panels 9, 10, 11, 12, 13
  • Whole breast radiotherapy reduces the 10-year risk of any first recurrence by 15% and the 15-year risk of breast cancer mortality by 4%, according to the American College of Oncology 11, 12, 13

Specific Criteria for Omitting Radiotherapy

  • The American College of Oncology suggests that radiotherapy can be safely omitted in women ≥65-70 years with T1N0, ER+/PR+, HER2-negative, grade 1-2 tumors who receive at least 5 years of adjuvant endocrine therapy 13
  • No lymphovascular invasion and no extensive intraductal component are required for radiotherapy omission, as recommended by the American College of Oncology 11, 12, 14

Critical Caveats and Pitfalls

  • Boost radiotherapy is mandatory for age <50 years, grade 3 tumors, presence of lymphovascular invasion, extensive intraductal component, and close or focally positive margins, according to the American College of Oncology 11, 12, 14
  • Accelerated partial breast irradiation (APBI) is an acceptable alternative to whole breast radiotherapy for low-risk patients, with criteria including age ≥50 years, unicentric/unifocal, node-negative, non-lobular, ≤3cm, no extensive intraductal component, no lymphovascular invasion, negative margins, and receiving endocrine therapy, as recommended by the American College of Oncology 9, 10, 11, 12, 15

REFERENCES